Randomized clinical trial of biodegradeable intraluminal sheath to prevent anastomotic leak after stapled colorectal anastomosis. BJS 2017; 104: 1010-1019.
Published: 10th May 2017
Authors: I. S. Bakker, A. N. Morks, H. O. ten Cate Hoedemaker, J. G. M. Burgerhof, H. G. Leuvenink, J. B. van Praagh et al.
Anastomotic leakage is a potential major complication after colorectal surgery. The C‐seal was developed to help reduce the clinical leakage rate. It is an intraluminal sheath that is stapled proximal to a colorectal anastomosis, covering it intraluminally and thus preventing intestinal leakage in case of anastomotic dehiscence. The C‐seal trial was initiated to evaluate the efficacy of the C‐seal in reducing anastomotic leakage in stapled colorectal anastomoses.
Between December 2011 and December 2013, 402 patients were included in the trial, 202 in the C‐seal group and 200 in the control group. Anastomotic leakage was diagnosed in 31 patients (7·7 per cent), with a 10·4 per cent leak rate in the C‐seal group and 5·0 per cent in the control group (
C‐seal application in stapled colorectal anastomoses does not reduce anastomotic leakage. Registration number:
You may also be interested in
Authors: M.E. Kelly, R. Glynn, A.G.J. Aalbers, M. Abraham‐Nordling, W. Alberda, A. Antoniou et al.
Notes: Complete resection is key
Randomized clinical trial
Randomized clinical trial of intracutaneously versus transcutaneously sutured ileostomy to prevent stoma‐related complications (ISI trial).
Authors: M. F. Sier, D. D. Wisselink, D. T. Ubbink, R. J. Oostenbroek, G. J. Veldink, B. Lamme et al.
Notes: More leaks with intracutaneous
Authors: S. J. Chapman, A. Pericleous, C. Downey, D. G. Jayne
Notes: No easy answers.
Randomized clinical trial
Authors: E. M. de Leede, N. J. van Leersum, H. M. Kroon, V. van Weel, J. R. M. van der Sijp, B. A. Bonsing et al.
Notes: Chewing gum no effect on recovery
Authors: E. J. Ryan, E. M. Creagh
Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer. BJS 2018; 105: e192-e203.
Authors: F. C. Koyama, C. M. Lopes Ramos, F. Ledesma, V. A. F. Alves, J. M. Fernandes, B. B. Vailati et al.
Notes: Molecular enhancement of treatment
Clinicopathological, genomic and immunological factors in colorectal cancer prognosis. BJS 2018; 105: e99-e109.
Authors: K. M. Marks, N. P. West, E. Morris, P. Quirke
Notes: Defines modern practice
Gut microbiome influences on anastomotic leak and recurrence rates following colorectal cancer surgery. BJS 2018; 105: e131-e141.
Authors: S. Gaines, C. Shao, N. Hyman, J. C. Alverdy
Notes: A neglected frontier
Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. BJS 2018; 105: e110-e120.
Authors: O. Nordgård, K. Tjensvoll, B. Gilje, K. Søreide
Notes: The inner space frontier
Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. BJS 2018; 105: e204-e211.
Authors: I. Ubink, W. J. van Eden, P. Snaebjornsson, N. F. M. Kok, J. van Kuik, W. M. U. van Grevenstein et al.
Notes: Mesenchymal subtype predominates
Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. BJS 2018; 105: 295-301.
Authors: H. Grut, S. Solberg, T. Seierstad, M. E. Revheim, T. S. Egge, S. G. Larsen et al.
Notes: Immunosuppression may not accelerate growth
Preliminary results of a cohort study of induction chemotherapy‐based treatment for locally recurrent rectal cancer. BJS 2018; 105: 447-452.
Authors: D. M. G. I. van Zoggel, S. J. Bosman, M. Kusters, G. A. P. Nieuwenhuijzen, J. S. Cnossen, G. J. Creemers et al.
Notes: Promising responses